Population pharmacokinetics of pevifoscorvir sodium (ALG-000184) in healthy participants and participants with chronic hepatitis B in support of phase 2 dose selection

• About Overview Management Board of Directors

• Science Pipeline Posters & Presentations

• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy

• News & Media Press Releases Presentations & Events

• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR

• Careers

• Overview

• Management

• Board of Directors

• Pipeline

• Posters & Presentations

• Chronic HBV Infection

• MASH

• Clinical Trials

• Expanded Access Policy

• Press Releases

• Presentations & Events

• Overview

• Stock Stock Quote & Chart Analyst Coverage

• News & Events News Releases Investor Calendar

• Financials SEC Filings Quarterly Results

• Governance Governance Highlights Committee Composition

• Resources Investor FAQs Email Alerts Contact IR

• Stock Quote & Chart

• Analyst Coverage

• News Releases

• Investor Calendar

• SEC Filings

• Quarterly Results

• Governance Highlights

• Committee Composition

• Investor FAQs

• Email Alerts

• Contact IR